Paper950592
Pharmacokinetics of isoniazid metabolism in man.
Ellard GA and 1 other. J Pharmacokinet Biopharm, 1976. Cited by 182 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Pharmacokinetics of isoniazid metabolism in man. Papers, record 950592. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/950592
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Isoniazid | Major topic |
| Acetylation | |
| Glycine | |
| Humans | |
| Isonicotinic Acids | |
| Kinetics |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 773,583 | Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. | Clin Pharmacol Ther | 1976 | https://conductscience.org/library/papers/773583 | PubMed |
| 2 | 6,032,052 | Kinetic considerations relating to the accrual and elimination of drug metabolites. | Br J Pharmacol Chemother | 1967 | https://conductscience.org/library/papers/6032052 | PubMed |
| 3 | 4,116,545 | General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis. | Bull Int Union Tuberc | 1972 | https://conductscience.org/library/papers/4116545 | PubMed |
| 4 | 5,916,738 | Comparative studies on the metabolism of isoniazid and isoniazid hydroazones in the dog. | Arch Int Pharmacodyn Ther | 1966 | https://conductscience.org/library/papers/5916738 | PubMed |
| 5 | 13,789,848 | A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and paraminosalicylic acid in man. | Am Rev Respir Dis | 1961 | https://conductscience.org/library/papers/13789848 | PubMed |
| 6 | 4,834,616 | Pharmacokinetic studies with an isoniazid slow-releasing matrix preparation. | Am Rev Respir Dis | 1974 | https://conductscience.org/library/papers/4834616 | PubMed |
| 7 | 4,452,938 | The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man. | J Pharmacokinet Biopharm | 1974 | https://conductscience.org/library/papers/4452938 | PubMed |
| 8 | 5,349,625 | A study of the availability of six commercial formulations of isoniazid. | Clin Pharmacol Ther | 1969 | https://conductscience.org/library/papers/5349625 | PubMed |
| 9 | 5,075,259 | The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine. | Biochem J | 1972 | https://conductscience.org/library/papers/5075259 | PubMed |
| 10 | 4,774,936 | The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine. | Tubercle | 1973 | https://conductscience.org/library/papers/4774936 | PubMed |
| 11 | 5,973,152 | Kinetics of competitive inhibition of salicylic acid conjugation with glycine in man. | Biochem Pharmacol | 1966 | https://conductscience.org/library/papers/5973152 | PubMed |
| 12 | 4,875,398 | Genetic factors in relation to drugs. | Annu Rev Pharmacol | 1968 | https://conductscience.org/library/papers/4875398 | PubMed |
| 13 | 4,109,735 | Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosis. | Lancet | 1972 | https://conductscience.org/library/papers/4109735 | PubMed |
| 14 | 5,855,885 | Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man. | J Pharmacol Exp Ther | 1965 | https://conductscience.org/library/papers/5855885 | PubMed |
| 15 | 14,046,608 | ASPECTS OF THE METABOLISM OF ISONIAZID AND ACETYLISONIAZID IN THE HUMAN AND THE DOG. | J Med Pharm Chem | 1962 | https://conductscience.org/library/papers/14046608 | PubMed |
| 16 | 4,556,778 | Isoniazid and psuedocholinesterase polymorphisms. | Fed Proc | 1972 | https://conductscience.org/library/papers/4556778 | PubMed |
| 17 | 1,216,339 | Determination of the acetylator phenotype using matrix isoniazid. | Tubercle | 1975 | https://conductscience.org/library/papers/1216339 | PubMed |
| 18 | 5,263,687 | Genetic variations in the acetylation of isoniazid and other drugs. | Ann N Y Acad Sci | 1968 | https://conductscience.org/library/papers/5263687 | PubMed |
| 19 | 5,435,232 | Rapid determination of isonicotinic acid hydrazide in whole blood with 2,4,6-trinitrobenzenesulphonic acid. | Clin Chim Acta | 1970 | https://conductscience.org/library/papers/5435232 | PubMed |
| 20 | 1,149,365 | Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. | Clin Pharmacol Ther | 1975 | https://conductscience.org/library/papers/1149365 | PubMed |
Cited by59
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 182 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,893,955 | Carbamate Prodrugs Restrict In Vivo Metabolism and Improve the Pharmacokinetics of Isoniazid. | ACS Cent Sci | 2025 | https://conductscience.org/library/papers/40893955 | PubMed |
| 40,741,006 | A scoping review about smoking, smoking cessation and their effects on anti-tuberculosis agents: insights into drug metabolisms, safety, and effectiveness. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40741006 | PubMed |
| 39,959,342 | Clinical perspectives of isoniazid-induced liver injury. | Liver Res | 2021 | https://conductscience.org/library/papers/39959342 | PubMed |
| 39,758,904 | A turn-on fluorescent probe containing a β-ketoester moiety for the selective detection of intracellular hydrazine. | RSC Adv | 2025 | https://conductscience.org/library/papers/39758904 | PubMed |
| 39,364,056 | Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39364056 | PubMed |
| 38,584,604 | Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38584604 | PubMed |
| 36,200,885 | The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives. | Clin Microbiol Rev | 2022 | https://conductscience.org/library/papers/36200885 | PubMed |
| 36,069,614 | Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36069614 | PubMed |
| 36,061,038 | Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs. | Lancet Reg Health Am | 2022 | https://conductscience.org/library/papers/36061038 | PubMed |
| 35,707,778 | Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy. | Glob Med Genet | 2022 | https://conductscience.org/library/papers/35707778 | PubMed |
| 35,510,229 | Defensive role of Nigella sativa against antituberculosis drugs induced renal toxicity. | Toxicol Res (Camb) | 2022 | https://conductscience.org/library/papers/35510229 | PubMed |
| 35,497,447 | A sensitive and selective fluorescent probe for hydrazine with a unique nonaromatic fluorophore. | RSC Adv | 2020 | https://conductscience.org/library/papers/35497447 | PubMed |
| 34,905,153 | Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. | Clin Pharmacokinet | 2022 | https://conductscience.org/library/papers/34905153 | PubMed |
| 34,635,182 | Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs. | BMC Pharmacol Toxicol | 2021 | https://conductscience.org/library/papers/34635182 | PubMed |
| 33,537,010 | Biochemical Characterization of Arylamine N-acetyltransferases From Vibrio vulnificus. | Front Microbiol | 2020 | https://conductscience.org/library/papers/33537010 | PubMed |
| 33,106,268 | Acetylation of Isoniazid Is a Novel Mechanism of Isoniazid Resistance in Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/33106268 | PubMed |
| 31,964,788 | N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/31964788 | PubMed |
| 31,591,118 | A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31591118 | PubMed |
| 30,767,706 | Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. | Pharmacogenomics | 2019 | https://conductscience.org/library/papers/30767706 | PubMed |
| 30,545,003 | Optimization and Validation of a Chromatographic Method for the Quantification of Isoniazid in Urine of Tuberculosis Patients According to the European Medicines Agency Guideline. | Antibiotics (Basel) | 2018 | https://conductscience.org/library/papers/30545003 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/950592
GET https://conductscience.org/api/papers/v1/950592/references?page=2